NervGen Pharma Corp. (NGENF)

1.5700 -0.1300 (-7.65%) At close: 03:56PM EDT

NervGen Pharma Corp.

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Canada
778-731-1711
https://www.nervgen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William Joseph Radvak BASc	Co-Founder & Chairman	165.71k	N/A	1963
Dr. Harold Martin Punnett D.M.D.	Co-Founder & Independent Director	N/A	N/A	N/A
Mr. William J. Adams C.A., CPA, CA, CPA	CFO & Corporate Secretary	276.47k	N/A	1962
Dr. Daniel D. Mikol M.D., Ph.D.	Chief Medical Officer	464.85k	N/A	N/A
Mr. Michael Kelly	CEO, President & Director	N/A	N/A	1966
Mr. Brian McAlister	Co-Founder & Advisor	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Corporate Governance

NervGen Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.